Cardiovascular benefits can increase Rybelsus’ competitiveness over other oral GLP-1RAs GlobalData Oct 29, 2024 The market for oral GLP-1RAs is expanding, and Rybelsus’ latest results showed its benefits in reducing the risk in cardiovascular…
GLP1 agonists set to become the best-selling drugs in 2024: GlobalData EP News Bureau Mar 15, 2024 Shift could reflect a changing demand away from oncology toward addressing metabolic disorders
